Advertisement
Advertisement

MDGL

MDGL logo

Madrigal Pharmaceuticals, Inc. Common Stock

523.69
USD
Sponsored
-16.20
-3.00%
May 15, 15:59 UTC -4
Closed
exchange

After-Market

526.50

+2.81
+0.54%

MDGL Earnings Reports

Positive Surprise Ratio

MDGL beat 23 of 42 last estimates.

55%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$357.79M
/
-$1.94
Implied change from Q1 26 (Revenue/ EPS)
+14.92%
/
-40.31%
Implied change from Q2 25 (Revenue/ EPS)
+68.13%
/
+2.11%

Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On May 06, 2026, MDGL reported earnings of -3.25 USD per share (EPS) for Q1 26, beating the estimate of -4.10 USD, resulting in a 20.92% surprise. Revenue reached 311.34 million, compared to an expected 306.78 million, with a 1.49% difference. The market reacted with a +7.42% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -1.94 USD, with revenue projected to reach 357.79 million USD, implying an decrease of -40.31% EPS, and increase of 14.92% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
May 13, 2026 For Q4 26
Estimate
-$24.25
Actual
$44.19
Surprise
+282.20%
logo
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.51
Actual
-$0.61
Surprise
-19.51%
logo
Aquestive Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+49.96%
logo
Altimmune, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.24
Actual
-$0.18
Surprise
+27.18%
logo
Prelude Therapeutics Incorporated
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.13
Surprise
+48.68%
logo
Achieve Life Sciences, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.19
Surprise
+39.59%
logo
Karyopharm Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.45
Actual
-$1.24
Surprise
+14.90%
logo
Journey Medical Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-1.14%
logo
Avita Medical, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.28
Actual
-$0.35
Surprise
-22.55%
logo
PolyPid Ltd. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.81%
FAQ
For Q1 2026, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$3.25, beating estimates by 20.92%, and revenue of $311.34M, 1.49% above expectations.
The stock price moved up 7.42%, changed from $502.47 before the earnings release to $539.73 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 13 analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$1.94 and revenue of $357.79M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement